Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Bethesda, Maryland 20892


RATIONALE: Analyzing genes that are present in cancer cells may be useful in developing better methods to detect, predict, and treat cutaneous T-cell lymphoma. PURPOSE: Clinical trial to study genes that are present in cutaneous T-cell lymphoma cells.

Study summary:

OBJECTIVES: - Identify gene expression patterns in malignant T cells that can be used to diagnose cutaneous T-cell lymphoma. - Determine the patterns of gene expression that distinguish normal skin-homing T cells from malignant T cells. OUTLINE: Patients are stratified by disease (Sezary syndrome vs mycosis fungoides) and prior treatment (yes vs no). All patients receive a physical examination, and a medical history is taken. Patients with Sezary syndrome undergo leukapheresis. Patients with plaque/tumor stage mycosis fungoides undergo skin biopsy of involved skin. Malignant T cells from blood or skin are then isolated and patterns of gene expression in the malignant T cells are compared to those in normal skin-homing T cells from healthy donors using a "gene chip" (Lymphochip). Patients are followed annually for 5 years. PROJECTED ACCRUAL: A total of 40 patients (20 per disease stratum) will be accrued for this study within 2 years.


DISEASE CHARACTERISTICS: - Histologically proven mycosis fungoides with 2 or more plaques or tumors greater than 1 cm in size OR - Immunologically proven Sezary syndrome with all of the following: - Erythroderma - Lymphadenopathy - T-cell receptor variable beta chain clonality greater than 10% of total lymphocytes by flow cytometry OR - CD4+CD7- T-cell fraction that represents greater than 10% of CD4+ T cells PATIENT CHARACTERISTICS: Age: - 18 to 85 Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - See Disease Characteristics Hepatic: - Not specified Renal: - Not specified Other: - Not pregnant or nursing - HIV-1 and HTLV-1 negative - No prior intravenous drug use PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - At least 2 months since prior systemic chemotherapy Endocrine therapy: - Not specified Radiotherapy: - At least 2 months since prior electron beam radiotherapy Surgery: - Not specified Other: - At least 2 weeks since prior topical therapy - At least 2 months since prior photopheresis - At least 2 months since prior psoralen ultraviolet light (PUVA) or ultraviolet B (UVB) therapy



Primary Contact:

Study Chair
Sam T. Hwang, MD, PhD
NCI - Dermatology Branch

Backup Contact:


Location Contact:

Bethesda, Maryland 20892
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.